YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy

• Main Authors: Wing Lam (Author), Mohammad Arammash (Author), Wei Cai (Author), Fulan Guan (Author), Zaoli Jiang (Author), Shwu-Huey Liu (Author), Peikwen Cheng (Author), Yung-Chi Cheng (Author)
• Formato: Libro
• Publicado: Frontiers Media S.A., 2023-10-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Introduction: Prostate cancer is the second leading cause of cancer death among men in the United States. Castration-Resistant Prostate Cancer (CRPC) often develops resistance to androgen deprivation therapy. Resistance in CRPC is often driven by AR variants and glucocorticoid receptor (GR). Thus, d...